Literature DB >> 22338593

Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients.

Birgitte Fagerlund1, Lars H Pinborg, Erik Lykke Mortensen, Lars Friberg, William F C Baaré, Anders Gade, Claus Svarer, Birte Y Glenthøj.   

Abstract

Studies of in vivo dopamine receptors in schizophrenia have mostly focused on D(2) receptors in striatal areas or on D(1) receptors in cortex. No previous study has examined the correlation between cortical dopamine D(2/3) receptor binding potentials and cognition in schizophrenia patients. The objective was to examine this relation in the frontal cortex in first-episode, drug-naive schizophrenia patients. Based on preclinical and pharmacological evidence, we specifically expected to find a relation between D(2/3) receptor binding potentials and set shifting. This was a cross-sectional, case-control study using single-photon emission computerized tomography with the D(2/3)-receptor ligand [(123)I]epidepride, co-registered with structural magnetic resonance imaging and correlated to cognitive measures. Participants were 24 antipsychotic-naive, first-episode schizophrenia patients and 20 healthy controls matched for gender and age. For patients, a significant linear correlation between D(2/3) BP(ND) and set shifting was found, while significant quadratic associations were observed for verbal fluency, planning and attention. For controls, the only significant association with D(2/3) BP(ND) was a quadratic partial correlation for set shifting. The main findings indicated a relation between D(2/3) receptor binding in the frontal cortex and set shifting, planning and attention, but also support a differential involvement of cortical dopamine D(2/3) receptor binding in at least some cognitive functions, perhaps particularly attention, in schizophrenia patients compared to healthy people. The results suggest that cortical D(2/3) receptor function may be more involved in some cognitive functions (i.e. attention, fluency and planning) in patients with schizophrenia than in healthy people, suggesting that information processing in schizophrenia may be characterized by lower signal:noise ratios.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22338593     DOI: 10.1017/S146114571200003X

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  6 in total

1.  ¹²⁴I-Epidepride: a PET radiotracer for extended imaging of dopamine D2/D3 receptors.

Authors:  Suresh Pandey; Archana Venugopal; Ritu Kant; Robert Coleman; Jogeshwar Mukherjee
Journal:  Nucl Med Biol       Date:  2014-01-31       Impact factor: 2.408

2.  The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia.

Authors:  Tanja Veselinović; Ingo Vernaleken; Hildegard Janouschek; Paul Cumming; Michael Paulzen; Felix M Mottaghy; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2018-05-01       Impact factor: 4.530

Review 3.  The Emerging Role of SPECT Functional Neuroimaging in Schizophrenia and Depression.

Authors:  Anil Kalyoncu; Ali Saffet Gonul
Journal:  Front Psychiatry       Date:  2021-12-15       Impact factor: 4.157

4.  Brain connectivity studies in schizophrenia: unravelling the effects of antipsychotics.

Authors:  Ayna B Nejad; Bjørn H Ebdrup; Birte Y Glenthøj; Hartwig R Siebner
Journal:  Curr Neuropharmacol       Date:  2012-09       Impact factor: 7.363

5.  Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.

Authors:  Henrik Nørbak-Emig; Bjørn H Ebdrup; Birgitte Fagerlund; Claus Svarer; Hans Rasmussen; Lars Friberg; Peter N Allerup; Egill Rostrup; Lars H Pinborg; Birte Y Glenthøj
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-29       Impact factor: 5.176

6.  In vivo absolute quantification of striatal and extrastriatal D2/3 receptors with [123I]epidepride SPECT.

Authors:  Stergios Tsartsalis; Benjamin B Tournier; Philippe Millet
Journal:  EJNMMI Res       Date:  2020-06-16       Impact factor: 3.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.